Mosaic caveolin-3 expression in acquired rippling muscle disease without evidence of myasthenia gravis or acetylcholine receptor autoantibodies
Harriet P Lo, Enrico Bertini, Massimiliano Mirabella, Ana Domazetovska, Russell C Dale, Stefania Petrini, Adele D'Amico, Enza Maria Valente, Rita Barresi, Mark Roberts, Giulia Tozzi, Giorgio Tasca, Sandra T Cooper, Volker Straub, Kathryn N North
Neuromuscular Disorders | PERGAMON-ELSEVIER SCIENCE LTD | Published : 2011
Awarded by Australian National Health and Medical Research Council
Awarded by TREAT-NMD
Awarded by Medical Research Council
The authors thank the patients for participation in this study, and Dr. John Watson for referring patient 1. This work has been supported by grants from the Australian National Health and Medical Research Council (KN North and ST Cooper #301946; KN North #403941 and HP Lo #206527). E. Bertini was supported by a grant from the Italian Ministry of Health and by the TREAT-NMD European Grant No. ISTRIPQA1. The Newcastle Muscle Centre is supported by the Muscular Dystrophy Campaign and the Diagnostic and Advisory Service for Rare Neuromuscular Diseases is funded by the NHS National Commissioning Group.